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Cancer stem cells (CSCs) have been reported in many human tumors and are proposed
to drive tumor initiation and progression. CSCs share a variety of biological properties
with normal somatic stem cells such as the capacity for self-renewal, the propagation
of differentiated progeny, and the expression of specific cell surface markers and stem
cell genes. However, CSCs differ from normal stem cells in their chemoresistance and
tumorigenic and metastatic activities. Despite their potential clinical importance, the
regulation of CSCs at the molecular level is not well-understood. MicroRNAs (miRNAs) are
a class of endogenous non-coding RNAs that play an important role in the regulation of
several cellular, physiological, and developmental processes. Aberrant miRNA expression
is associated with many human diseases including cancer. miRNAs have been implicated
in the regulation of CSC properties; therefore, a better understanding of the modulation
of CSC gene expression by miRNAs could aid the identification of promising biomarkers
and therapeutic targets. In the present review, we summarize the major findings on
the regulation of CSCs by miRNAs and discuss recent advances that have improved
our understanding of the regulation of CSCs by miRNA networks and may lead to the
development of miRNA therapeutics specifically targeting CSCs.
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BACKGROUND
The CSC theory, which is based on the concept that cancer
might arise from a rare population of cells with stem cell prop-
erties, was proposed approximately 150 years ago (Cohnheim,
1875; Wicha et al., 2006). Recent technological developments
(flow cytometry analysis and cell sorting) and the establishment
of new animal models have provided evidence supporting the
CSC theory. Moreover, CSCs are resistant to conventional treat-
ments and are therefore not only of academic interest, but may
also be an important consideration in clinical practice. Therefore,
a better understanding of the characteristics of CSCs and the
identification of therapeutic agents capable of targeting the CSC
population are critical issues. Cancer researchers have investigated
protein-coding genes and products, including surface markers
that are involved in the self-renewal and asymmetric cell division
of CSCs. Recently, in addition to alterations in protein-coding
genes, abnormalities in non-coding RNAs [miRNAs and long
intergenic non-coding RNAs] have been observed in various types
of cancers and have been shown to play important roles in the
regulation of CSC properties such as asymmetric cell division,
tumorigenicity, and drug resistance. In the present review, we
discuss the general features of CSCs and the role of miRNAs
in the regulation of CSC properties, and summarize the current
therapeutic strategies targeting miRNAs for CSC therapy.
BIOGENESIS AND FUNCTIONS OF miRNAs
miRNAs are 21–25 nucleotides long, non-coding RNAs that
regulate gene expression at the post-transcriptional level by
binding to the 3′-untranslated regions (3′UTRs) or the open read-
ing frames of target genes, leading to the degradation of target
mRNAs or repression of mRNA translation (Iorio and Croce,
2012). miRNAs are transcribed for the most part by RNA poly-
merase II as long primary transcripts characterized by hairpin
structures (pri-miRNA), and are processed in the nucleus by
RNase III Drosha into 70–100 nucleotide long precursor miRNAs
(pre-miRNAs) in combination with cofactors such as DGCR8,
an evolutionarily conserved protein that interacts with proline-
rich peptides through its WW domain (Gregory et al., 2004; Lee
et al., 2004) (Figure 1).DGCR8 is located on chromosome region
22q11.2, whose heterozygous deletion results in the most com-
mon human genetic deletion syndrome, known as DiGeorge syn-
drome. The clinical symptoms of the disease are highly variable
and in approximately 75% of patients, congenital heart defects
are observed (Shiohama et al., 2003; Yamagishi and Srivastava,
2003). The product of pri-miRNA cleavage, the pre-miRNA, is
exported to the cytoplasm by exportin-5, a member of the Ran-
dependent nuclear transport receptor family (Lee et al., 2004)
and further cleaved in a complex composed of RNase III Dicer
and the transactivating response RNA- binding protein (TRBP)
into a miRNA:miRNA∗ complex. While one of the two strands is
selected as a guide strand, the complementary strand (miRNA∗)
is usually degraded (Iorio and Croce, 2012). miRNA∗ was origi-
nally considered to have no function and to be degraded; however,
recent evidence suggests that it can be used as a functional strand
andmay play significant biological roles (Uchino et al., 2013; Yang
et al., 2013).
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FIGURE 1 | miRNA biogenesis and function. miRNAs are transcribed by
RNA polymerase II or III as pri-miRNA, and are processed in the nucleus by
Drosha-DGCR8 into pre-miRNAs. The product of pri-miRNA cleavage, the
pre-miRNA, is exported to the cytoplasm by exportin-5 and further cleaved in
a complex composed of Dicer and TRBP. The functional strand of mature
miRNA is incorporated into the RNA-induced silencing complex (RISC), which
contains GW182 and Argonaute protein. As a part of this complex, the
mature miRNA regulates gene expression by binding to partially
complementary sequences in the 3′UTRs of target mRNAs, leading to mRNA
degradation or translation inhibition.
The mature miRNA is incorporated into a complex known as
the RNA-induced silencing complex (RISC), which contains the
GW182 and Argonaute proteins. As a part of this complex, the
mature miRNA regulates gene expression by binding to partially
complementary sequences in the 3′UTRs of target mRNAs, lead-
ing to mRNA degradation or translation inhibition (Iorio and
Croce, 2012). Several studies have reported that miRNAs also
bind to the 5′UTR or the open reading frame (Orom et al., 2008;
Mandke et al., 2012) and can promote the translation of their tar-
get genes under growth arrest conditions (Vasudevan et al., 2007).
Recently, Nishi et al. showed that TNRC6A, a human GW182
paralog, shuttles Ago2 into the nucleus and the colocalization
of Ago2-TNRC6A with miRNAs mediates gene silencing (Nishi
et al., 2013).
MICRORNAs REGULATE PLURIPOTENCY AND
DIFFERENTIATION
The discovery of two miRNAs, lin-4 and let-7, in Caenorhabditis
elegans suggested that miRNAs are important regulators of
embryonic development and stem cell functions in mammals
(Lee et al., 1993; Pasquinelli et al., 2000; Reinhart et al., 2000).
The function of miRNAs in mouse and human embryonic stem
cells (ESCs) has been investigated using cells lacking Dicer1 and
DGCR8, which are critical for miRNA biogenesis. Deletion of
Dicer1 leads to embryonic lethality inmice (Bernstein et al., 2003)
and DGCR8-deficient mouse ESCs show alterations in the regu-
lation of the cell cycle and differentiation that are associated with
failure to silence stemness markers, such as Oct4, Rex1, Sox2, and
Nanog, as well as delayed expression of differentiation markers
(Wang et al., 2007).
In a comparative transcriptome analysis, Dicer1-deficient
mouse ESCs lacking miRNAs showed a significant increase
in transcripts containing a GCACUU motif in the 3′UTR
(Sinkkonen et al., 2008). This sequence is complementary to
the AAGUGC seed sequence of the miR-290-295 cluster (miR-
290, miR-291a, miR-292, miR-291b, miR-294, and miR-295) and
the miR-302/367 cluster (miR-302a, miR-302b, miR-302c, miR-
302d, and miR-367) in mouse ESCs. Using a similar approach,
novel stem cell-specificmiRNAswere initially identified in human
ESCs. These miRNAs include two clusters: miR-302/367 and the
miR-371 cluster (miR-372 and miR-373). The expression of the
miR-371 cluster is downregulated before that of the miR-302/367
cluster, suggesting a temporal hierarchy in the duration of specific
miRNA activity (Stadler et al., 2010; Kim et al., 2011). Members
of the miR-302 family rescue the proliferation defects of DGCR8-
mutant mouse ESCs (Wang et al., 2008) and reprogram human
skin cancer cells into a pluripotent ESC-like state (Lin et al., 2008).
The Let-7 family is another critical regulator of ESC differenti-
ation. Mature let-7 family members are essentially absent in ESCs
and accumulate only upon ESC differentiation (Viswanathan
et al., 2008). Melton et al. reported that whereas transfection
of let-7c into wild-type cells had no effect on the expression
of pluripotency genes, let-7c rescued the differentiation defect
in DGCR8−/− cells by downregulating Oct4, Sox2, and Nanog
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(Melton et al., 2010). Lin-28, a marker of undifferentiated ESCs,
is also used to induce pluripotent stem cells (Yu et al., 2007b). A
negative feedback loop between Lin-28 and let-7 family members
precisely controls the levels of these miRNAs. Although Lin-28
regulates the expression of let-7 miRNAs by binding to the pre-
cursors and blocking their maturation, the let-7 family is highly
expressed and targets Lin-28 mRNA in mouse differentiated cells
and embryonic carcinoma cells (Yu et al., 2007b) (Figure 2).
Members of themiR-34 family ofmiRNAs are direct targets of p53
and function as tumor suppressors, inhibiting reprogramming
through the repression of pluripotency genes such asNanog, Sox2,
andN-myc (Choi et al., 2011) (Figure 2). Since the cell cycle regu-
lator p21 also represses reprogramming efficiency, these findings
suggest that p53 represses pluripotency via two distinct mecha-
nisms. Evidence that let-7 and miR-34 family members are tumor
suppressor miRNAs (Takamizawa et al., 2004; Johnson et al.,
2005; Tazawa et al., 2007) suggests that stem cell-specific miRNAs
play important roles in tumor initiation and development.
miRNA REGULATION IN CANCER
miRNAs play a crucial role in the progression of human cancer,
and expression profiling in human malignancies has identified
FIGURE 2 | miRNA in stem cells and cancer stem cells. Stem
cell-specific miRNAs play important roles in tumor initiation and
development. During normal development, pluripotent stem cells become
more restricted to specific cell lineages. Progenitor cells are committed to
generating different cell types, whereas fully differentiated cells have a low
potential for self-renewal. The expression levels of miR-34 and let-7 family
members increase during differentiation. During cancer development, CSC
properties are regulated by the balance between miRNA expression and
the expression of miRNA target genes.
signatures associated with cancer development, progression,
and prognosis (Liu et al., 2012; Volinia and Croce, 2013).
Chromosomal regions coding for oncogenic miRNAs that are
involved in the negative regulation of a tumor suppressor gene
can be amplified in association with cancer development. This
amplification would result in the upregulation of oncogenic miR-
NAs and silencing of tumor suppressor genes (He et al., 2005).
On the other hand, miRNAs targeting oncogenes are often located
in fragile site, where deletions or mutations can occur, leading to
the reduction or loss of miRNAs and the overexpression of their
target oncogenes. Dysregulation ofmiRNA expression affects pro-
cesses associated with cancer progression such as the induction
of anti-apoptotic activity, drug resistance, tissue invasion, and
metastasis (Cimmino et al., 2005; Tavazoie et al., 2008; To et al.,
2008). Recent evidence suggests that miRNAs are involved in
tumor initiation through the regulation of CSC properties such as
self-renewal ability, tumorigenicity and drug-resistance (Yu et al.,
2007a; Shimono et al., 2009; Song et al., 2013a,b).
CSCs
Accumulating lines of evidence suggest that CSCs share a variety
of biological properties with normal somatic stem cells such as the
capacity for self-renewal, the propagation of differentiated pro-
genitors, and the expression of specific stem cell genes (Colmont
et al., 2012). However, CSCs differ from normal stem cells in
their chemoresistance and tumorigenic and metastatic activities
(Colmont et al., 2012 and Table 1). In addition, recently glyco-
sylation patterns are found to be different between normal stem
cells and CSCs (Karsten and Goletz, 2013). The CSC theory is
generally accepted in the field of cancer research, not only in basic
research but also with regard to cancer drug discovery.
Normal stem cells and CSCs act via common signaling path-
ways that regulate self-renewal activity, including Wnt, Notch,
Table 1 | Representative cell surface markers for human CSCs.
Cancer type CSC marker References
AML CD34+/CD38− Bonnet and Dick, 1997
Breast CD44+/CD24−/low Al-Hajj et al., 2003
ALDH1 Ginestier et al., 2007
Glioma CD133 Singh et al., 2003, 2004
Colon CD133 O’brien et al., 2007;
Ricci-Vitiani et al., 2007
CD44/EpCAM/CD166 Dalerba et al., 2007
Metastatic Colon CD133+/CD26+ Pang et al., 2010
Melanoma CD20 Fang et al., 2005
CD271 Boiko et al., 2010
Pancreatic ESA/CD44/CD24 Hermann et al., 2007
Metastatic Pancreatic CD133/CXCR4 Li et al., 2007a
Prostate CD44/a2β1/CD133 Collins et al., 2005
Lung CD133 Eramo et al., 2008
Hepatic EpCAM/AFP Yamashita et al., 2010
Gastric CD44 Takaishi et al., 2009
AML, acute myelogenous leukemia; ALDH, aldehyde dehydrogenase; EpCAM,
epithelial cell adhesion molecule; CXCR4, CXC chemokine receptor 4; AFP, alpha-
fetoprotein.
www.frontiersin.org January 2014 | Volume 4 | Article 295 | 3
Takahashi et al. microRNAs and cancer stem cells
and Sonic Hedgehog, and dysregulation of these pathways plays
a role in tumor initiation and development (Reya et al., 2001).
Jamieson et al. showed that aberrations in the Wnt/β-catenin
pathway enhance self-renewal activity during leukemia stem cell
propagation (Jamieson et al., 2004). Korkaya et al. reported that
the Wnt/β-catenin pathway is involved in the regulation of nor-
mal and malignant mammary stem/progenitor cell populations
(Korkaya et al., 2009). Several studies have shown that the Notch
pathway is activated in breast, glioblastoma, and colon CSCs
(Hoey et al., 2009; Taketo, 2011). Alterations in Hedgehog signal-
ing have been reported in colon, breast, and glioblastoma CSCs
(Liu et al., 2006; Varnat et al., 2009; Takezaki et al., 2011).
The development of fluorescent antibodies, flow cytometry,
and cell sorting techniques enabled the identification of cell popu-
lations possessing CSC properties. Furthermore, the development
of severely immunodeficient mouse strains facilitated the evalua-
tion of tumor formation ability. These methods have enabled the
identification and isolation of CSCs from various cancers (Bonnet
andDick, 1997; Al-Hajj et al., 2003; Collins et al., 2005; Fang et al.,
2005; Ginestier et al., 2007; Hermann et al., 2007; Li et al., 2007a;
Eramo et al., 2008; Takaishi et al., 2009; Boiko et al., 2010; Pang
et al., 2010; Yamashita et al., 2010) (Table 1). In this review, we
discuss the major findings of recent studies highlighting the roles
of certain “CSC-specific” miRNAs in representative cancer types
(Table 2). From these discussions, we present an emerging theme
that several miRNAs may exert a functional role in the regulation
of the key biological properties of CSCs.
LEUKEMIA STEM CELLS
Through an integrated approach that combined miRNA expres-
sion analysis and bioinformatic prediction of mRNA targets,
distinct miRNA signatures were shown to fine-tune each step
of hematopoiesis, including the reconstitution potential of
hematopoietic stem cells (Arnold et al., 2011). The miR-17-92
cluster functions as an oncogenic miRNA by enhancing the for-
mation of Myc-driven B-cell lymphomas in a mouse model (He
et al., 2005). Single miRNAs function as oncogenes. The overex-
pression of miR-155 in early B-cells leads to polyclonal expansion
of the pro-B-cell compartment (Costinean et al., 2006), and retro-
viral expression of miR-155 in immature mouse hematopoietic
cells resulted in the expansion of granulocyte/monocyte popu-
lations displaying pathological features characteristic of myeloid
neoplasia without progression to acute myeloid leukemia (AML)
(O’connell et al., 2008). Recently, dysregulation of single miRNAs
was shown to contribute to hematological malignancies, includ-
ing AML and myelodysplastic syndrome (Han et al., 2010; Song
et al., 2013a). Han et al. reported that miR-29a regulates early
hematopoiesis and induces AML by converting myeloid progen-
itors into self-renewing leukemia stem cells via targeting several
tumor suppressors and cell cycle regulators (Han et al., 2010).
miR-22-induced inhibition of the ten-eleven-translocation gene
2 (TET2) tumor suppressor increased the methylation of TET2
target genes, such as Aim2, Hal, Igbt2, and Sp140, and resulted in
positive effects on hematopoietic stem cell self-renewal and trans-
formation. This has led to the suggestion that mir-22 is associated
with myelodysplastic syndrome and hematological malignancies
(Song et al., 2013a).
BREAST CSCs
The first solid tumor CSCs were identified in and isolated
from breast tumors in 2003 (Al-Hajj et al., 2003). Al-Hajj et
al. described a CD44+/CD24−/low cell population that had a
markedly high tumor-initiating capacity. In 2007, Yu et al. iden-
tified let-7 as a master regulator of breast CSC properties (Yu
et al., 2007a). In breast CSCs, reduced let-7 expression con-
trols self-renewal and differentiation through RAS and HMGA2,
respectively (Figure 2). Since HMGA2 plays a role in the control
of differentiation and proliferation of both human and mouse
ESCs (Li et al., 2007b), these findings also suggest that let-7
is involved in the growth and differentiation of ESCs beyond
tumorigenesis.
Epithelial-to-mesenchymal transition (EMT) is an evolution-
arily conserved process that occurs during embryonic develop-
ment in many species of mammals (Liu et al., 2006). Since the
EMT program is often activated during tumor invasion and
metastasis, the genetic controls and biochemical mechanisms
underlying the acquisition of invasiveness and the subsequent sys-
temic spread of cancer cells have been areas of intensive research.
The EMT phenotype is characterized by the downregulation of
epithelial markers such as E-cadherin, the expression of mes-
enchymal markers such as N-cadherin and vimentin, the loss of
cell-cell contact and cell polarity, and the acquisition of cell inva-
sive capabilities. Mani et al. reported that EMT is also associated
with the acquisition of CSC properties (Mani et al., 2008). A
CD44+/CD24−/low cell population purified from cancer tissues
shows the features of an EMT phenotype, and human cancer cells
induced to undergo EMT exhibit a CD44+/CD24−/low antigen
phenotype and high tumorigenicity.
Recently, two studies reported the clinical relevance of CSCs in
breast cancer specimens (Giordano et al., 2013; Yu et al., 2013). In
early breast cancer patients, the presence of CD44+/CD24−/low
cells in bone marrow was indicative of a poor prognosis
(Giordano et al., 2013). Circulating tumor cells (CTCs) in breast
cancer patients also showed the EMT phenotype (Yu et al., 2013).
Progressive disease patients undergoing therapy had a higher
number of mesenchymal marker positive CTCs than epithelial
marker positive CTCs. These results suggest that the CSC phe-
notype is clinically important not only as a therapeutic target
but also as a potential biomarker for the prognostic evaluation
of patients undergoing cancer treatment.
A molecular link between EMT and the miR-200 family is
provided by the zinc-finger E-box-binding homeobox protein
encoding genes (ZEB1/ZEB2) (Gregory et al., 2008; Park et al.,
2008). The miR-200 family consists of five members that are clas-
sified into two clusters: miR−200a, miR−200b, and miR−429
on human chromosome 1; and miR−200c and miR−141 on
human chromosome 12 (Gregory et al., 2008). Expression of the
miR-200 family strongly inhibits the EMT phenotype induced
by TGF-β, and a reciprocal feedback loop between the miR-
200 family and the ZEB family of transcription factors tightly
regulates both EMT and mesenchymal-to-epithelial transition
(Burk et al., 2008). MiR-200 family members are downregulated
in normal human and mouse mammary stem cells and breast
CSCs, and miR-200c inhibits the formation of mammary ducts
from mammary stem cells and tumor formation from breast
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Table 2 | The regulatory roles of miRNAs in CSCs.
Cancer Type miRNA Target gene Role of miRNA in CSC properties References
Leukemia (AML and MDS) miR-22 TET2 Promotion of self-renewal Song et al., 2013a
Breast Let-7 RAS and HMGA2 Inhibition of self-renewal and de-differentiation Yu et al., 2007a
miR-200 family ZEB1/ZEB2 Inhibition of EMT Gregory et al., 2008
BMI-1 Inhibition of self-renewal Shimono et al., 2009
SUZ12 Inhibition of mammosphere formation Iliopoulos et al., 2010
miR-22 TET family (TET1 -3) Suppression of miR-200 family expression Song et al., 2013b
Brain miR-9/9*, miR-17 CAMTA1 Promotion of CD133+ cell proliferation Schraivogel et al., 2011
miR-128 BMI-1 Inhibition of self-renewal Godlewski et al., 2008
miR-199b-5p HES1 Reduction of the CD133+ cell fraction Garzia et al., 2009
Colon miR-193 PLAU and K-RAS Inhibition of tumorigenicity and invasiveness Iliopoulos et al., 2011
miR-451 MIF and COX-2 Inhibition of self-renewal and tumorigenicity Bitarte et al., 2011
miR-34a NOTCH 1 Suppression of asymmetric cell division Bu et al., 2013
Prostate miR-34a CD44 Inhibition of self-renewal and metastasis Liu et al., 2011
miR-320 β-catenin Inhibition of Wnt/β-catenin pathway Hsieh et al., 2013
AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome.
CSCs (Shimono et al., 2009). Members of the miR-200 family
also modulate the self-renewal ability of CSCs by targeting B-
lymphoma Mo-MLV insertion region 1 homolog (BMI-1) and
SUZ12, a subunit of a polycomb repressor complex (Iliopoulos
et al., 2010). BMI-1 regulates the self-renewal and differentia-
tion of several types of stem cells, including hematopoietic, brain,
and mammary stem cells (Molofsky et al., 2003; Park et al.,
2003; Pietersen et al., 2008). Therefore, modulation of the activ-
ity of the miR-200 family using conventional therapy could be a
promising approach to improve the effectiveness of breast cancer
treatments.
Normal human and mouse mammary stem cells can be iso-
lated and characterized on the basis of their aldehyde dehydro-
genase (ALDH) activities (Ginestier et al., 2007). Using ALDH
activity, Ibara et al. determined that miR-205 and miR-22 were
highly expressed in mouse mammary progenitor cells (Ibarra
et al., 2007). MiR-22 was recently shown to be an epigenetic mod-
ifier that promotes stemness and metastasis in breast cancer by
directly targeting enzymes in the TET family, which regulate DNA
demethylation (Song et al., 2013b). The TET family is involved
in the demethylation of the miR-200 promoter, and miR-22 pro-
motes CSC properties such as EMT and a metastatic phenotype
through the suppression of the miR-200 family. This provides the
first evidence that chromatin-remodeling systems with opposing
effects on cell fate (self-renewal vs. differentiation) are regulated
by opposing sets of miRNAs.
BRAIN CSCs
The pentaspan membrane glycoprotein CD133, also known as
Prominin-1, was first identified as a marker of hematopoietic
stem cells and progenitor cells, and was subsequently used to
detect malignancies (Miraglia et al., 1997; Yin et al., 1997). In
solid cancers, CD133 was first used to identify CSCs in different
types of human brain tumors including glioblastoma, medul-
loblastoma, and ependymomas (Singh et al., 2003, 2004; Yu
et al., 2010). In these studies, patient tumor cells were separated
based on the expression of CD133. The CD133+ cell popula-
tion is highly tumorigenic in vivo, whereas CD133− cells do not
form tumors even at high numbers (Singh et al., 2003, 2004; Yu
et al., 2010). CD133+ cells are also resistant to radiation and
chemotherapy. These findings led to the hypothesis that glioblas-
tomas are maintained by CSCs, and that this treatment-resistant
subpopulation is a promising target for effective therapies. CD133
has been instrumental for the identification of CSCs in colorec-
tal (Ricci-Vitiani et al., 2007) and pancreatic (Hermann et al.,
2007) carcinomas. CD133 itself is a marker of normal neural stem
cells in both humans (Uchida et al., 2000) and mice (Lee et al.,
2005).
In cancer cells, the deacetylase HDAC6 directly interacts with
and regulates the intracellular localization of CD133 (Mak et al.,
2012). CD133 forms a stable protein complex with HDAC6 and
β-catenin, which leads to the activation of β-catenin signaling
targets in different types of cancer. CD133 is also associated
with phosphoinositide 3-kinase (PI3K) 85 kDa regulatory sub-
unit (p85) in glioma stem cells (GSCs) (Wei et al., 2013). The
PI3K pathway is a key regulator of tumorigenesis in glioblastoma
and other cancers (Godlewski et al., 2010). Therefore, activa-
tion of the PI3K/Akt pathway by the physical interaction between
CD133 and p85 promotes tumorigenicity in GSCs. The function
of CD133 in brain tumors should be fully characterized in the
near future, which may shed light on the role of CD133 as a
functional marker of GSCs.
www.frontiersin.org January 2014 | Volume 4 | Article 295 | 5
Takahashi et al. microRNAs and cancer stem cells
Schraivogel et al. reported that miR-9, miR-9∗ (miR-9/9∗),
miR-17, and miR-106b are highly abundant in the CD133+ cell
population in glioblastoma cell lines. Among the upregulated
miRNAs in the CD133+ cell population, inhibition of miR-9/9∗
or miR-17 leads to reduced neurosphere formation and stim-
ulates cell differentiation. Functional analysis of these miRNAs
showed that miR-9/9∗ and miR-17 target calmodulin-binding
transcription activator 1 (CAMTA1), a putative transcription
factor of the anti-proliferative cardiac hormone natriuretic pep-
tide A (NPPA). Clinical studies also demonstrated that CAMTA1
and NPPA expression is correlated with patient survival. These
findings could provide a basis for the design of novel treatment
strategies for glioblastoma (Schraivogel et al., 2011).
MiR-124 and miR-128 are the most highly expressed miRNAs
in the adult brain and are preferentially expressed in neurons
(Smirnova et al., 2005). Patients with high-grade glioma show
significant downregulation of miR-128 expression. Functional
analyses showed that miR-128 expression inhibits glioma cell pro-
liferation in vitro and glioma xenograft growth in vivo (Godlewski
et al., 2008). In addition, miR-128 specifically inhibits the self-
renewal capacity of GSCs by directly targeting BMI-1, a polycomb
family transcriptional repressor required for postnatal mainte-
nance of neural stem cells in the peripheral and central nervous
system (Molofsky et al., 2003). Since BMI-1 maintains neural
stem cells in an undifferentiated self-renewing state, the regula-
tion of BMI-1 by miR-128 may contribute to normal stem cell
regulation.
Another study showed that miR-199b-5p downregulation was
associated with metastatic spread in medulloblastoma. In medul-
loblastoma cells, miR-199b-5p directly targets HES1, a transcrip-
tion factor of the Notch signaling pathway (Garzia et al., 2009).
During brain development, Notch functions as a critical regula-
tor of cell fate, by which gliogenesis can only occur when Notch
signaling specifically represses the neuronal pathway in progen-
itor cells (Karamboulas and Ailles, 2013). MiR-199b-5p blocks
Notch signaling, inhibiting the self-renewal capacity of medul-
loblastoma cells by reducing the CD133+ subpopulation (Garzia
et al., 2009). Recently, miR-34a was shown to regulate Notch sig-
naling by targetingNotch-1 andNotch-2 in medulloblastoma cells
(Li et al., 2009). Therefore, miR-199b-5p and miR-34a are impor-
tant for the self-renewal potential of GSCs via the Notch signaling
pathway.
COLON CSCs
CD133 was initially used to identify and isolate colon CSCs
(O’brien et al., 2007; Ricci-Vitiani et al., 2007), which was fol-
lowed by the identification of CD44, epithelial surface antigen
(EpCAM), and CD166 as alternative colon CSCmarkers (Dalerba
et al., 2007). CD166 is a mesenchymal stem cell marker whose
expression is correlated with poor prognosis in colon cancer
patients (Weichert et al., 2004). Compared to CD44−/EpCAMlow
cells, CD44+/EpCAMhigh cells from primary tumors show high
tumorigenic activity in NOD/SCID mice. Moreover, CD166+
cells in the CD44+/EpCAMhigh cell fraction contribute to the
tumorigenic activity of colon CSCs. In addition to CD133, CD44,
EpCAM, and CD166, the expression of leucine-rich repeat-
containing G-protein-coupled receptor 5 (Lgr5) varies among
colorectal cancer (CRC) cases and is significantly correlated with
lymphatic and vascular invasion, lymph node metastasis, and
drug resistance (Vermeulen et al., 2008;Merlos-Suarez et al., 2011;
Kobayashi et al., 2012).
Iliopoulos et al. reported that the expression of miR-193a is
inversely correlated withK-RAS and plasminogen activator uroki-
nase (PLAU) expression in human colon adenocarcinomas, and
that miR-193 expression inhibits tumorigenicity and invasiveness
by directly targeting K-RAS and PLAU, respectively (Iliopoulos
et al., 2011). MiR-451 is another regulator of CSC properties such
as self-renewal, tumorigenicity, and drug resistance. In spheroid
cell culture, downregulation of miR-451 induces the upregulation
of macrophage migration inhibitory factor (MIF) and COX-2,
resulting in the acquisition of self-renewal and tumorigenic prop-
erties (Bitarte et al., 2011). MIF and Cox-2 are involved in the
activation of the Wnt pathway, which is functionally essential for
the maintenance of colon CSCs (Vermeulen et al., 2010), suggest-
ing that miR-451 could regulate the properties of colon CSCs by
suppressing the Wnt pathway.
Notch signaling is frequently activated in CRCs, and is dysreg-
ulated directly by epigenetic and genetic changes and indirectly
by synergistic interactions with the Wnt pathway, which is also
activated in CRC (Taketo, 2011). Notch signaling promotes the
self-renewal activity of intestine and colon stem cells (Taketo,
2011). Therefore, colon CSCs in CRC are thought to arise from,
or at least share common properties with, normal colon stem
cells (Clevers, 2011; O’brien et al., 2012). Bu et al. reported
that miR-34a determines whether colon CSCs undergo symmet-
ric or asymmetric division, and that inhibition of asymmetric
cell division suppresses tumorigenicity (Bu et al., 2013). MiR-34a
inhibits Notch signaling by directly targeting Notch receptors (Li
et al., 2009), suggesting that the upregulation of miR-34a weak-
ens Notch signaling and promotes the generation of daughter
cells (non-CSCs), whereas low miR-34a levels promote Notch
signaling and lead to the maintenance of CSCs. This study also
demonstrated that the expression level of miR-34a correlates
more closely with the differentiation of daughter cells than the
presence of Numb, which also suppresses Notch signaling by
promoting the degradation of membrane-bound Notch and its
intracellular domain (Bu et al., 2013).
PROSTATE CSCs
In prostate cancer (PCa), α2β1 integrin, CD133, and CD44 were
initially used to identify and isolate CSCs (Collins et al., 2005;
Patrawala et al., 2006, 2007). Patrawala et al. reported that CD44+
PCa cells have higher proliferative, tumorigenic, and metastatic
potentials than CD44− PCa cells (Patrawala et al., 2006), and
showed that androgen receptor (AR)-negative CD44+ PCa cells
differentiate into AR-positive CD44− PCa cells. Consistent with
this report, prostate-specific antigen (PSA)-negative or -low PCa
cells that are resistant to androgen ablation have a highly tumori-
genic phenotype (Qin et al., 2012). In addition, PSA−/low PCa
cells generate PSA+ PCa cells through asymmetric cell division,
and highly tumorigenic PSA−/low PCa cells are characterized by
an ALDH+/CD44+/α2β1 integrin+ phenotype (Qin et al., 2012).
Liu et al. reported that miR-34a is downregulated in CD44+
PCa cells purified from xenografts and primary tumors, and
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that miR-34a directly regulates the expression of CD44 at the
post-transcriptional level by binding to its 3′UTR (Liu et al.,
2011). Expression of miR-34a in CD44+ PCa cells inhibits tumor
migration and metastasis in a xenograft model (Liu et al., 2011),
and miR-34a inhibits Notch and AR signaling in PCa cells (Li
et al., 2009; Kashat et al., 2012), suggesting that miR-34a sup-
presses the self-renewal activity of CSCs in PCa cells.
Another miRNA that regulates CSC properties is miR-320,
which acts by directly targeting β-catenin in PCa cells (Hsieh et al.,
2013). miR-320 and β-catenin expression is inversely correlated
in CD44+ PCa cells. Furthermore, gene expression profiling of
miR-320-overexpressing PCa cells showed a significant decrease
in downstream target genes of the Wnt/β-catenin pathway and
CSC markers (Hsieh et al., 2013).
THERAPEUTIC APPROACHES TO TARGET CSCs
The development of therapies against CSCs has resulted in the
establishment of a new generation of cancer therapeutics, which
is particularly important in the treatment of intractable cancers.
Since CSCs are molecularly distinct from non-CSCs and bulk
tumor cells, a high-throughput screening approach was used to
identify small compounds that eliminate or reduce levels of CSCs
(Gupta et al., 2009; Sachlos et al., 2012). Gupta et al. identified
salinomycin as a selective inhibitor of breast CSCs (Gupta et al.,
2009) by screening a library of 16,000 natural and commercial
chemical compounds in a search for small compounds capable of
killing breast CSCs. Although the precise molecular mechanisms
underlying the elimination of CSCs by salinomycin are not fully
understood, several studies have improved our understanding of
the mechanisms and pharmacological action of salinomycin in
human CSCs (Fuchs et al., 2010; Lu et al., 2011; Tang et al.,
2011). Systemic salinomycin therapy induces a marked regres-
sion of subcutaneous thoracal metastases of breast cancer, and
combination therapy of salinomycin with erlotinib resulted in sig-
nificant tumor regression in metastatic squamous cell carcinoma
(Naujokat and Steinhart, 2012).
High-throughput screening using neoplastic and normal
human pluripotent stem cells (hPSC) showed that among 590
compounds, only thioridazine significantly promoted differentia-
tion of neoplastic hPSCs but not of normal hPSCs (Sachlos et al.,
2012). Thioridazine acts through dopamine receptors (dopamine
receptor1-5) (Seeman and Lee, 1975), indicating that its selective
interference with human CSCs is mediated by dopamine receptor
antagonism.
The development of therapies against CSCs is challenging
because both bulk cancer cells and CSCs must be eliminated. As
CSCs are molecularly distinct from bulk tumor cells, they can
be targeted by exploiting their molecular differences as described
above (Tables 1, 2). One of the most promising approaches
is the cell based delivery of miRNAs or miRNA inhibitors.
Several studies demonstrated that miRNAs are secreted through
“exosomes,” which are small endosome-derived vesicles (30–
100 nm) secreted from different cell types, such as dendritic
cells, hepatocyte, and tumor cells (Mittelbrunn et al., 2011; Luga
et al., 2012; Ramakrishnaiah et al., 2013). The exosome secreted
from mesenchymal stem cells (MSC) is selectively transferred
to the glioblastoma multiforme (GBM) (Munoz et al., 2013).
Since miR-9 is involved in the upregulation of p-glycoprotein,
Munoz et al. developed anMSC derived exosome containing anti-
miR-9 that efficiently suppressed p-glycoprotein expression in the
temozolomide-resistant GBM.
The glycosylation pattern of CSC markers on CSCs is differ-
ent from normal stem cells (Karsten and Goletz, 2013). Some
CSC markers such as CD44 and CD133 are also expressed in
normal stem and progenitor cells (Karsten and Goletz, 2013),
which might have negative implications for the development
of CSC-targeted delivery. This problem could be addressed by
the development of liposomes or nanoparticles conjugated to
antibodies against CSC specific glycans that permit the selective
delivery of CSC suppressive miRNAs or small molecules.
Recent studies have shown that several dietary compounds can
directly or indirectly affect the properties of CSCs (Li et al., 2011).
Therefore, natural dietary compounds have received increasing
attention in cancer chemoprevention, and several natural com-
pounds that induce the elimination or differentiation of breast
CSCs have been identified (Kakarala et al., 2010; Li et al., 2010;
Hagiwara et al., 2012). Resveratrol is a non-toxic natural product
that is found in grapes, berries, peanuts and red wine (Aziz et al.,
2003). Nowadays, resveratrol is widely consumed as a nutritional
supplement (Prasad, 2012), and its multifaceted biological effects
include anti-mutagenic and anti-cancer properties (Prasad, 2012;
Patel et al., 2013). Hagiwara et al. found that resveratrol enhances
miRNA functions through the upregulation of Ago2 expression,
which leads to the suppression of CSC properties (Hagiwara
et al., 2012). These results suggest that the identification of non-
toxic natural compounds capable of suppressing the properties of
CSCs through the regulation of miRNA expression is a promising
approach to support conventional chemotherapy.
CONCLUSIONS
Accumulating lines of evidence have shown that the heterogene-
ity and plasticity of cancer cells is reflected in the transition
from a non-CSC to a CSC phenotype. Therefore, clinical oncol-
ogists and cancer researchers need to determine which cancer
cells have the potential to contribute to tumor initiation and pro-
gression, including therapeutic resistance and metastasis. Several
studies reviewed here have shown that miRNAs can function
as tumor suppressors or oncogenes and play important roles in
various aspects of CSC properties. In this regard, miRNAs are
considered to be functional markers of CSCs. Therefore, a more
detailed understanding of the function ofmiRNAs in CSC biology
may improve cancer treatments and possibly lead to the clini-
cal application of miRNAs in cancer diagnosis, treatment, and
prognosis.
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